Idiopathic Pulmonary Fibrosis Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Pirfenidone, Nintedanib, others), By Route of Administration (Parenteral, Oral, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

2.25 billion

CAGR (2023-2028)

5.94%

Fastest Growing Segment

Hospitals & Clinics

Largest Market

North America

 

Market Overview

Global Idiopathic Pulmonary Fibrosis Market has valued at USD 2.25 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.94% through 2028. The lung condition idiopathic pulmonary fibrosis (IPF) is dangerous. When you breathe in, oxygen enters your bloodstream through small air sacs in your lungs. It then makes its way to your inside organs. Your lungs get congested with scar tissue because of IPF. With time, it becomes worse. Like the scars you receive on your skin after a cut, the IPF scar tissue is dense. It inhibits the transfer of oxygen from your lungs to your blood, which might prevent your body from functioning properly. Idiopathic pulmonary fibrosis can exist for a very long time without any symptoms showing up. When someone is exposed to anything like pollution, certain medications, or an illness, they may develop pulmonary fibrosis. Doctors are unsure of what causes IPF, though.

Diagnosing IPF involves a combination of medical history, physical examination, lung function tests, high-resolution computed tomography (HRCT) scans, and, in some cases, a lung biopsy. IPF is often challenging to diagnose because its symptoms can overlap with those of other lung diseases. Improved diagnostic techniques, such as high-resolution computed tomography (HRCT) and the identification of biomarkers, have enabled earlier and more accurate detection of IPF. This has increased the number of patients seeking treatment. The ongoing research and development of new drugs and therapies for IPF have led to the introduction of novel treatments, which expand the available options for patients. The approval of innovative therapies is a driving force in the market. Increased awareness campaigns and educational initiatives about IPF symptoms and the importance of early diagnosis have resulted in more patients seeking medical care. Healthcare professionals are also better equipped to recognize the disease. The focus on patient-centered care, including support groups, patient advocacy, and improving the quality of life for IPF patients, has become a driving factor in the market. Patient advocacy organizations play a crucial role in raising awareness and improving patient care.

Key Market Drivers

Advancements in Diagnosis

High-Resolution Computed Tomography (HRCT) imaging has become a gold standard in diagnosing IPF. It provides detailed images of the lungs, allowing healthcare professionals to detect characteristic patterns of fibrosis. HRCT is non-invasive and has significantly improved the accuracy of IPF diagnosis. Ongoing research into biomarkers, such as specific proteins or genetic markers, has the potential to aid in early diagnosis and disease monitoring. Identifying biomarkers associated with IPF can help distinguish it from other lung conditions. Minimally invasive lung biopsy techniques, such as transbronchial cryobiopsy and endobronchial ultrasound-guided biopsy, offer alternatives to traditional surgical biopsies. These techniques provide tissue samples for analysis, aiding in the confirmation of IPF diagnosis.

Multi-Disciplinary Discussion (MDD) approach involves a team of specialists, including radiologists, pulmonologists, and pathologists, who jointly evaluate patient data, imaging, and biopsy results. This collaborative approach enhances the accuracy of IPF diagnosis. AI and machine learning algorithms have been applied to HRCT scans and other patient data to improve diagnostic accuracy. These technologies can assist in identifying patterns and characteristics of IPF that may be missed by human observers. Telemedicine has become a valuable tool, especially during the COVID-19 pandemic. It allows healthcare professionals to remotely assess patients, review diagnostic images, and provide consultation for individuals in remote or underserved areas. Genetic testing for specific gene mutations associated with familial IPF can help confirm the diagnosis in cases where a family history of the disease is present. International guidelines and consensus statements, such as those from the American Thoracic Society (ATS) and the European Respiratory Society (ERS), have provided standardized criteria for diagnosing IPF, facilitating consistency in diagnosis. Improved understanding of the clinical presentation and symptoms of IPF has enabled healthcare providers to diagnose the disease more accurately. Common symptoms include progressive breathlessness and dry cough. Bronchoalveolar Lavage (BAL) is a diagnostic procedure that involves collecting fluid from the air sacs in the lungs. It can help rule out other lung diseases and contribute to the diagnostic process. This factor will help in the development of the Global Idiopathic Pulmonary Fibrosis Market.

Increasing Drug Development and Approval

The introduction of new IPF drugs provides healthcare professionals with a broader range of treatment options. This is particularly important because IPF is a complex and progressive disease with limited available therapies. Ongoing research and development efforts aim to improve the efficacy of IPF treatments. New drugs often offer better outcomes, slowing the progression of fibrosis and improving lung function, which can significantly benefit patients. The availability of new, effective medications increases patient access to treatments that may improve their quality of life. It can also be especially important for patients who have not responded well to existing therapies. The entry of new drugs into the market creates competition, potentially leading to price reductions and improved access for patients. Competition can also drive pharmaceutical companies to develop more innovative and effective treatments. The IPF market generates significant revenue, and the development of new drugs represents a substantial economic opportunity for pharmaceutical companies. This financial incentive encourages research and development in the field.

Drug development for IPF often involves clinical trials, which can contribute to the growth of the IPF market. Clinical trials provide opportunities for patients to access cutting-edge treatments and therapies. Regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are essential for the market. Approvals signify the safety and efficacy of new treatments, instilling confidence in healthcare providers and patients. As new drugs receive approvals, they often become available in various regions around the world. This expansion contributes to the global growth of the IPF market. Collaborative efforts between pharmaceutical companies, research institutions, and academic centers help advance drug development and bring innovative therapies to the market. New treatments aim not only to slow the progression of IPF but also to improve patients' quality of life by reducing symptoms and increasing functional capacity. With the introduction of new treatments, the IPF market expands, creating opportunities for healthcare professionals, drug manufacturers, and related services. This factor will pace up the demand of the Global Idiopathic Pulmonary Fibrosis Market

Growing Demand of Biologics and Targeted Therapies

Biologics and targeted therapies are designed to target specific disease pathways or mechanisms. They offer a more personalized and precise approach to treating IPF, potentially improving treatment outcomes. Compared to broad-spectrum medications, biologics and targeted therapies may have fewer side effects because they specifically target the underlying causes of the disease. This can lead to improved tolerability and patient compliance. Targeted therapies are often developed based on a deep understanding of the molecular mechanisms of IPF. This leads to treatments that can be highly effective in managing the disease, which is particularly important for a condition with limited treatment options. Biologics and targeted therapies have the potential to modify the course of the disease, slowing down or even halting the progression of fibrosis. This can significantly improve the prognosis for IPF patients.

The introduction of biologics and targeted therapies expands the IPF market by providing new treatment options. This contributes to the overall growth of the market and may encourage further research and development in the field. Increasing availability of biologics and targeted therapies enhances patient access to innovative treatments. This can be especially important for patients who do not respond well to traditional therapies. The entry of biologics and targeted therapies into the market creates competition, which can lead to price reductions, improving affordability and access for patients. Regulatory approvals for these therapies signify their safety and efficacy. These approvals build confidence among healthcare providers and patients, driving demand. As biologics and targeted therapies receive approvals, they often become available in various regions worldwide, contributing to the global expansion of the IPF market. Collaborative efforts between pharmaceutical companies, research institutions, and academic centers are essential for the development of biologics and targeted therapies. These efforts help advance research and bring innovative treatments to the market. This factor will accelerate the demand of the Global Idiopathic Pulmonary Fibrosis Market

Download Free Sample Report

Key Market Challenges

High Cost of Treatment

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and often progressive disease that requires long-term treatment. The high cost of medications, therapy, and healthcare services can impose a substantial financial burden on patients and their families, potentially leading to financial stress. Some IPF treatments, especially newer and more advanced therapies, may not be fully covered by health insurance plans. This can result in out-of-pocket expenses for patients, making it difficult for them to access necessary treatments. The high cost of IPF treatment can create disparities in access to care. Patients with limited financial resources may face barriers to accessing the most effective therapies, leading to disparities in outcomes. The cost of treatment can impact patients' adherence to prescribed medications and therapies. Patients may reduce or skip doses due to cost concerns, which can affect the effectiveness of the treatment. The high cost of IPF treatment places a financial burden on healthcare systems and insurance providers, potentially limiting the availability of certain treatments or leading to increased healthcare costs for society.  High treatment costs can lead to financial toxicity, which has a negative impact on patients' overall well-being. This can include increased stress, anxiety, and reduced quality of life. Pharmaceutical companies face significant research and development costs when developing new IPF treatments. The high cost of development and regulatory approval can contribute to the high prices of these therapies once they reach the market. High costs can lead some patients to discontinue or delay their treatment, which may result in disease progression and more severe health outcomes.

Limited Treatment Options

Idiopathic Pulmonary Fibrosis (IPF) is a progressive and often fatal lung disease, and the limited treatment options mean that many patients have few options to slow down or halt the progression of the disease. This can result in a poor prognosis for those affected. The limited number of effective therapies for IPF can leave healthcare providers with few tools to manage the disease. This can lead to a sense of frustration when trying to provide the best care for their patients.

Patients diagnosed with IPF may experience significant frustration and anxiety when they learn about the limited treatment options. This can affect their mental and emotional well-being. The lack of specific treatments for IPF can sometimes result in delayed diagnosis as healthcare providers rule out other conditions. This can lead to lost time for early intervention. Managing symptoms and improving the quality of life for IPF patients can be challenging due to the limited therapeutic options. This leaves many patients dealing with breathlessness, cough, and fatigue without effective relief. The limited treatment options can lead to treatment gaps where patients may not have appropriate therapies to manage the disease. This can result in a poor overall patient experience. The lack of effective treatments may also limit the incentives for pharmaceutical companies to invest in IPF research and development, potentially slowing the pace of innovation. The limited treatment options highlight significant unmet medical needs in the IPF field. There is a clear need for more effective therapies to address this devastating condition. The limited treatment options can place a burden on healthcare systems as they struggle to manage the disease and provide care for patients with few effective options.

Key Market Trends

Research into Genetic and Environmental Factors

Research into genetic factors helps identify individuals who may be at a higher risk of developing IPF. This knowledge can lead to personalized screening and preventative strategies. Genetic and environmental research may reveal biomarkers that can be used for early detection and diagnosis of IPF, enabling healthcare providers to intervene at an earlier, potentially more treatable stage of the disease. Identifying genetic and environmental risk factors allows for risk assessment and counseling for individuals with a family history of IPF or who have been exposed to certain environmental triggers.

Genetic research can help identify specific pathways and mechanisms underlying IPF. This knowledge may lead to the development of targeted therapies that address the root causes of the disease. Understanding the genetic and environmental factors contributing to an individual's IPF can inform the development of personalized treatment plans, optimizing therapy for each patient's unique needs. Research into environmental factors, such as exposure to certain toxins or pollutants, can help identify strategies for reducing exposure and preventing the development or exacerbation of IPF. Patients with IPF may benefit from genetic counseling to understand the hereditary aspects of the disease, particularly in cases of familial IPF. Insights gained from genetic and environmental research can uncover novel therapeutic targets, which may lead to the development of innovative treatments for IPF.

Segmental Insights

Drug Type Insights

In 2022, the Global Idiopathic Pulmonary Fibrosis Market largest share was held by pirfenidone segment and is predicted to continue expanding over the coming years. Pirfenidone has been proven effective in slowing the progression of IPF and improving lung function in some patients. It was one of the first drugs to receive approval for the treatment of IPF, which has contributed to its market dominance. It was among the early entrants into the IPF market, receiving approval in certain regions ahead of other treatments. Its early introduction gave it a head start in market penetration. Pirfenidone has a long history in the IPF market. It was one of the first drugs available for the condition, and this extended presence has established its reputation and familiarity among healthcare professionals and patients. It has also gained regulatory approvals in various countries, contributing to its market dominance. These approvals have expanded its global reach and market share. Over the years, clinical trials and real-world data have provided substantial evidence supporting the efficacy of pirfenidone in managing IPF. This data has reinforced its use as a standard treatment option.

Distribution Channel Insights

In 2022, the Global   Idiopathic Pulmonary Fibrosis Market largest share was held by hospital pharmacies segment in the forecast period and is predicted to continue expanding over the coming years.  In some regions, a significant proportion of IPF patients receive treatment on an inpatient basis, particularly during acute exacerbations or advanced stages of the disease. Hospital pharmacies are responsible for dispensing and managing medications for these inpatients. Hospitals often play a key role in conducting clinical trials for new IPF treatments. The distribution and management of trial medications may involve hospital pharmacies. IPF treatment can involve complex medication regimens, including the use of oxygen therapy, immunosuppressive drugs, and other specialized medications. Hospital pharmacies are equipped to handle these complex regimens. Regional healthcare regulations and reimbursement policies can influence the distribution of medications. In some cases, regulations or policies may favour or require hospital-based distribution of certain medications.

Download Free Sample Report

Regional Insights

The North America region dominates the Global Idiopathic Pulmonary Fibrosis Market in 2022. North America, particularly the United States and Canada, boasts well-developed and advanced healthcare infrastructure. This includes a network of specialized treatment centers, experienced healthcare professionals, and state-of-the-art medical facilities. These resources are essential for the diagnosis and management of IPF. North America has implemented screening programs and awareness campaigns that contribute to early diagnosis of IPF. Early detection is crucial for effective management and treatment of the disease. The region is a hub for pharmaceutical and biotechnology companies involved in the research and development of IPF treatments. This has led to a greater number of clinical trials and innovative therapies being available in North America. North America often has earlier access to newly approved IPF drugs and therapies. Regulatory agencies like the U.S. Food and Drug Administration (FDA) have expedited review processes for certain IPF treatments, which accelerates their availability in the market.

Recent Developments

  • In May 2023, Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug Application (IND) related to a Phase II study focusing on patients with Idiopathic Pulmonary Fibrosis, which is the most common form of progressive fibrosing interstitial lung disease. Consequently, Cumberland is set to initiate its FIGHTING FIBROSIS trial, with plans to enroll 128 patients across more than 20 leading medical centers in the United States. In this development, Idiopathic Pulmonary Fibrosis (IPF) emerges as the latest addition to Cumberland's clinical program, involving their first new chemical entity, ifetroban – a powerful and selective thromboxane receptor antagonist. The company has devised a Phase II clinical trial aimed at assessing the safety, tolerability, and effectiveness of oral ifetroban in patients with IPF. Recent research has demonstrated ifetroban's ability to both prevent and promote the resolution of lung fibrosis in various preclinical models.
  • In April 2022, Alembic Pharmaceuticals Limited (Alembic) received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) related to Pirfenidone Tablets in both 267 mg and 801 mg strengths. This approved ANDA is considered therapeutically equivalent to the reference listed drug product (RLD) Esbriet Tablets, available in 267 mg and 801 mg variants, which is marketed by Genentech, Inc. These Pirfenidone Tablets are specifically indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Alembic had previously obtained tentative approval for this ANDA. It's worth noting that this medication may not be suitable for certain other uses, mainly due to unexpired exclusivities associated with the reference listed drug for those uses.
  • In May 2022, Sandoz, a prominent player in the generic and biosimilar medicines industry, officially launched its generic pirfenidone in the United States. This generic version is the first fully substitutable equivalent (AB-rated) to Genentech's Esbriet and is intended for the treatment of idiopathic pulmonary fibrosis (IPF). Patients can now access this prescription oral medication through specialty pharmacies, and eligible patients can benefit from a $0 co-pay program. IPF is a progressive and incurable rare disease characterized by irreversible lung scarring, resulting in breathing difficulties. It primarily affects adults aged 50 and older, with a higher incidence among men. In the U.S., approximately 140,000 individuals are living with IPF. Alongside medications that can slow the progression of scar tissue formation, patients are advised to maintain an active lifestyle, adhere to a nutritious diet, and follow prescribed oxygen therapy.

Key Market Players

  • Boehringer Ingelheim
  • F. Hoffmann-La Roche AG
  • Cipla Ltd.
  • Shionogi & Co., Ltd.
  • Bristol-Myers Squibb Co.
  • United Therapeutics
  • FibroGen, Inc.
  • Pliant Therapeutics
  • Galecto Inc.
  • CSL Behring

By Drug Type

By Route of Administration

By Distribution Channel

By Region
  • Pirfenidone
  • Nintedanib
  • others
  • Oral
  • Parenteral
  • Others
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Idiopathic Pulmonary Fibrosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Idiopathic Pulmonary Fibrosis Market, By Drug Type:

o   Pirfenidone

o   Nintedanib

o   others

  • Idiopathic Pulmonary Fibrosis Market, By Route of Administration

o   Oral

o   Parenteral

o   Others

  • Idiopathic Pulmonary Fibrosis Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

  • Idiopathic Pulmonary Fibrosis Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Idiopathic Pulmonary Fibrosis Market.

Available Customizations:

Global Idiopathic Pulmonary Fibrosis Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Idiopathic Pulmonary Fibrosis Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]               

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.   Markets Covered

1.2.2.   Years Considered for Study

1.2.3.   Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Idiopathic Pulmonary Fibrosis Market Outlook

5.1.  Market Size & Forecast

5.1.1.         By Value

5.2.  Market Share & Forecast

5.2.1.         By Drug Type (Pirfenidone, Nintedanib, others)

5.2.2.         By Route of Administration (Parenteral, Oral, Others)

5.2.3.         By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

5.2.4.         By Region

5.2.5.         By Company (2022)

5.3.  Market Map

6.    Asia Pacific Idiopathic Pulmonary Fibrosis Market Outlook

6.1.  Market Size & Forecast

6.1.1.         By Value

6.2.  Market Share & Forecast

6.2.1.         By Drug Type

6.2.2.         By Route of Administration

6.2.3.         By Distribution Channel

6.2.4.         By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.         China Idiopathic Pulmonary Fibrosis Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Drug Type

6.3.1.2.2.             By Route of Administration

6.3.1.2.3.             By Distribution Channel

6.3.2.         India Idiopathic Pulmonary Fibrosis Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Drug Type

6.3.2.2.2.             By Route of Administration

6.3.2.2.3.             By Distribution Channel

6.3.3.         Australia Idiopathic Pulmonary Fibrosis Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Drug Type

6.3.3.2.2.             By Route of Administration

6.3.3.2.3.             By Distribution Channel

6.3.4.         Japan Idiopathic Pulmonary Fibrosis Market Outlook

6.3.4.1.         Market Size & Forecast

6.3.4.1.1.             By Value

6.3.4.2.         Market Share & Forecast

6.3.4.2.1.             By Drug Type

6.3.4.2.2.             By Route of Administration

6.3.4.2.3.             By Distribution Channel

6.3.5.         South Korea Idiopathic Pulmonary Fibrosis Market Outlook

6.3.5.1.         Market Size & Forecast

6.3.5.1.1.             By Value

6.3.5.2.         Market Share & Forecast

6.3.5.2.1.             By Drug Type

6.3.5.2.2.             By Route of Administration

6.3.5.2.3.             By Distribution Channel

7.    Europe Idiopathic Pulmonary Fibrosis Market Outlook

7.1.  Market Size & Forecast

7.1.1.         By Value

7.2.  Market Share & Forecast

7.2.1.         By Drug Type

7.2.2.         By Route of Administration

7.2.3.         By Distribution Channel

7.2.4.         By Country

7.3.  Europe: Country Analysis

7.3.1.         France Idiopathic Pulmonary Fibrosis Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Drug Type

7.3.1.2.2.             By Route of Administration

7.3.1.2.3.             By Distribution Channel

7.3.2.         Germany Idiopathic Pulmonary Fibrosis Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Drug Type

7.3.2.2.2.             By Route of Administration

7.3.2.2.3.             By Distribution Channel

7.3.3.         Spain Idiopathic Pulmonary Fibrosis Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Drug Type

7.3.3.2.2.             By Route of Administration

7.3.3.2.3.             By Distribution Channel

7.3.4.         Italy Idiopathic Pulmonary Fibrosis Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Drug Type

7.3.4.2.2.             By Route of Administration

7.3.4.2.3.             By Distribution Channel

7.3.5.         United Kingdom Idiopathic Pulmonary Fibrosis Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Drug Type

7.3.5.2.2.             By Route of Administration

7.3.5.2.3.             By Distribution Channel

8.    North America Idiopathic Pulmonary Fibrosis Market Outlook

8.1.  Market Size & Forecast

8.1.1.         By Value

8.2.  Market Share & Forecast

8.2.1.         By Drug Type

8.2.2.         By Route of Administration

8.2.3.         By Distribution Channel

8.2.4.         By Country

8.3.  North America: Country Analysis

8.3.1.         United States Idiopathic Pulmonary Fibrosis Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Drug Type

8.3.1.2.2.             By Route of Administration

8.3.1.2.3.             By Distribution Channel

8.3.2.         Mexico Idiopathic Pulmonary Fibrosis Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Drug Type

8.3.2.2.2.             By Route of Administration

8.3.2.2.3.             By Distribution Channel

8.3.3.         Canada Idiopathic Pulmonary Fibrosis Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Drug Type

8.3.3.2.2.             By Route of Administration

8.3.3.2.3.             By Distribution Channel

9.    South America Idiopathic Pulmonary Fibrosis Market Outlook

9.1.  Market Size & Forecast

9.1.1.         By Value

9.2.  Market Share & Forecast

9.2.1.         By Drug Type

9.2.2.         By Route of Administration

9.2.3.         By Distribution Channel

9.2.4.         By Country

9.3.  South America: Country Analysis

9.3.1.         Brazil Idiopathic Pulmonary Fibrosis Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Drug Type

9.3.1.2.2.             By Route of Administration

9.3.1.2.3.             By Distribution Channel

9.3.2.         Argentina Idiopathic Pulmonary Fibrosis Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Drug Type

9.3.2.2.2.             By Route of Administration

9.3.2.2.3.             By Distribution Channel

9.3.3.         Colombia Idiopathic Pulmonary Fibrosis Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Drug Type

9.3.3.2.2.             By Route of Administration

9.3.3.2.3.             By Distribution Channel

10.  Middle East and Africa Idiopathic Pulmonary Fibrosis Market Outlook

10.1.              Market Size & Forecast

10.1.1.      By Value

10.2.              Market Share & Forecast

10.2.1.      By Drug Type

10.2.2.      By Route of Administration

10.2.3.      By Distribution Channel

10.2.4.      By Country

10.3.              MEA: Country Analysis

10.3.1.      South Africa Idiopathic Pulmonary Fibrosis Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Drug Type

10.3.1.2.2.           By Route of Administration

10.3.1.2.3.           By Distribution Channel

10.3.2.      Saudi Arabia Idiopathic Pulmonary Fibrosis Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Drug Type

10.3.2.2.2.           By Route of Administration

10.3.2.2.3.           By Distribution Channel

10.3.3.      UAE Idiopathic Pulmonary Fibrosis Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Drug Type

10.3.3.2.2.           By Route of Administration

10.3.3.2.3.           By Distribution Channel

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Recent Developments

12.2.              Product Launches

12.3.              Mergers & Acquisitions

13.  Global Idiopathic Pulmonary Fibrosis Market: SWOT Analysis

14.  Porter’s Five Forces Analysis

14.1.              Competition in the Industry

14.2.              Potential of New Entrants

14.3.              Power of Suppliers

14.4.              Power of Customers

14.5.              Threat of Substitute Product

15.  PESTLE Analysis

16.  Competitive Landscape

16.1.    Boehringer Ingelheim

16.1.1.      Business Overview

16.1.2.      Company Snapshot

16.1.3.      Products & Services

16.1.4.      Financials (In case of listed companies)

16.1.5.      Recent Developments

16.1.6.      SWOT Analysis

16.2.    F. Hoffmann-La Roche AG

16.2.1.      Business Overview

16.2.2.      Company Snapshot

16.2.3.      Products & Services

16.2.4.      Financials (In case of listed companies)

16.2.5.      Recent Developments

16.2.6.      SWOT Analysis

16.3.    Cipla Ltd

16.3.1.      Business Overview

16.3.2.      Company Snapshot

16.3.3.      Products & Services

16.3.4.      Financials (In case of listed companies)

16.3.5.      Recent Developments

16.3.6.      SWOT Analysis

16.4.    Shionogi & Co., Ltd.

16.4.1.      Business Overview

16.4.2.      Company Snapshot

16.4.3.      Products & Services

16.4.4.      Financials (In case of listed companies)

16.4.5.      Recent Developments

16.4.6.      SWOT Analysis

16.5.    Bristol-Myers Squibb Co.

16.5.1.      Business Overview

16.5.2.      Company Snapshot

16.5.3.      Products & Services

16.5.4.      Financials (In case of listed companies)

16.5.5.      Recent Developments

16.5.6.      SWOT Analysis

16.6.    United Therapeutics

16.6.1.      Business Overview

16.6.2.      Company Snapshot

16.6.3.      Products & Services

16.6.4.      Financials (In case of listed companies)

16.6.5.      Recent Developments

16.6.6.      SWOT Analysis

16.7.    FibroGen, Inc

16.7.1.      Business Overview

16.7.2.      Company Snapshot

16.7.3.      Products & Services

16.7.4.      Financials (In case of listed companies)

16.7.5.      Recent Developments

16.7.6.      SWOT Analysis

16.8.    Pliant Therapeutics

16.8.1.      Business Overview

16.8.2.      Company Snapshot

16.8.3.      Products & Services

16.8.4.      Financials (In case of listed companies)

16.8.5.      Recent Developments

16.8.6.      SWOT Analysis

16.9.    Galecto Inc.

16.9.1.      Business Overview

16.9.2.      Company Snapshot

16.9.3.      Products & Services

16.9.4.      Financials (In case of listed companies)

16.9.5.      Recent Developments

16.9.6.      SWOT Analysis

16.10.  CSL Behring

16.10.1.    Business Overview

16.10.2.    Company Snapshot

16.10.3.    Products & Services

16.10.4.    Financials (In case of listed companies)

16.10.5.    Recent Developments

16.10.6.    SWOT Analysis

17.  Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Idiopathic Pulmonary Fibrosis Market was estimated to be USD 2.25 billion in 2022.

down-arrow

Boehringer Ingelheim, F. Hoffmann-La Roche AG are some of the key players operating in the Global Idiopathic Pulmonary Fibrosis Market.

down-arrow

The high cost of treatment presents challenges in terms of accessibility and affordability for patients and healthcare systems.

down-arrow

Emerging trends included the development of biologics and targeted therapies that aimed to address the underlying mechanisms of IPF, focusing on fibrosis and inflammation pathways.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Global Idiopathic Pulmonary Fibrosis Market to grow with a CAGR of 5.94%

Nov, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Idiopathic Pulmonary Fibrosis Market.

Why Choose Us